Table 3 Enriched GO biological processes terms in hub genes of PPI network for six cancer type datasets.
Cancer types | GO terms | Description | P value | FDR | Genes |
|---|---|---|---|---|---|
LUAD | GO:0000281 | Mitotic cytokinesis | 4.70E–06 | 6.71E–04 | ANLN, RACGAP1, KIF4A, KIF20A |
GO:0007018 | Microtubule-based movement | 1.88E–05 | 0.001341272 | RACGAP1, KIF4A, KIF14, KIF20A | |
GO:0051301 | Cell division | 6.46E–05 | 0.003080959 | ASPM, CDK1, KIF14, NCAPG, SPC25 | |
BLCA | GO:0050852 | T cell receptor signaling pathway | 1.00E–06 | 2.05E–04 | ZAP70, LCK, CD3G, CD247, CD3D |
GO:0045059 | Positive thymic T cell selection | 1.06E–05 | 0.001076609 | ZAP70, CD3G, CD3D | |
GO:0007169 | Transmembrane receptor protein tyrosine kinase signaling pathway | 2.53E–05 | 0.001290254 | EPHA4, ZAP70, SRC, LCK | |
HNSC | GO:0019221 | Cytokine-mediated signaling pathway | 3.76E–07 | 5.41E–05 | CSF3, CXCL8, CCL20, IL1B, CXCL2 |
GO:0030593 | Neutrophil chemotaxis | 7.03E–07 | 5.41E–05 | CXCL8, CCL20, IL1B, CXCL2 | |
GO:0006955 | Immune response | 1.80E–06 | 9.26E–05 | CSF3, CXCL8, CCL20, IL1B, CXCL2 | |
LGG | GO:0000079 | Regulation of cyclin-dependent protein serine/threonine kinase activity | 1.06E–04 | 0.006378325 | CCNB1, GADD45A, PKMYT1 |
GO:0051301 | Cell division | 1.45E–04 | 0.006378325 | WEE1, CCNB1, PTTG1, NUF2 | |
GO:0000086 | G2/M transition of mitotic cell cycle | 7.65E–04 | 0.022440237 | WEE1, CCNB1, PKMYT1 | |
LUSC | GO:0031639 | Plasminogen activation | 2.94E–06 | 1.73E–04 | FGA, APOH, FGG |
GO:0007160 | Cell-matrix adhesion | 2.94E–04 | 0.008039642 | FGA, FGG, ITGAX | |
GO:0002576 | Platelet degranulation | 4.09E–04 | 0.008039642 | FGA, APOH, FGG | |
SKCM | GO:0060337 | Type I interferon signaling pathway | 2.98E–12 | 3.10E–10 | BST2, STAT1, IRF1, GBP2, PSMB8, IFIT3 |
GO:0051607 | Defense response to virus | 2.91E–05 | 0.001510741 | BST2, STAT1, IRF1, IFIT3 | |
GO:0060333 | Interferon-gamma-mediated signaling pathway | 2.03E–04 | 0.007032439 | STAT1, IRF1, GBP2 |
